olvi-vec
Generic: olvimulogene nanivacirepvec·Code: GLV-1h68, GL-ONC1
olvi-vec: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| GENELUX Corp (GNLX) | Phase 1/Phase 2 |
FDA Decisions
FDA_MeetingFDA indicated that a clinically meaningful PFS advantage in the absence of a decrement in OS could potentially support traditional approval.(GNLX)
Frequently asked questions
Who is developing olvi-vec?
olvi-vec is being developed by GENELUX Corp.
What is olvi-vec's latest FDA decision?
The most recent tracked FDA decision for olvi-vec is FDA_Meeting for FDA indicated that a clinically meaningful PFS advantage in the absence of a decrement in OS could potentially support traditional approval., dated March 25, 2025.
Get deeper analysis on olvi-vec
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis